Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SNNA

Sienna Biopharmaceuticals (SNNA) Stock Price, News & Analysis

Sienna Biopharmaceuticals logo

About Sienna Biopharmaceuticals Stock (NASDAQ:SNNA)

Advanced Chart

Key Stats

Today's Range
$0.11
$0.17
50-Day Range
$0.14
$0.14
52-Week Range
$0.06
$3.80
Volume
13.32 million shs
Average Volume
1.87 million shs
Market Capitalization
$4.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.

Receive SNNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sienna Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNNA Stock News Headlines

Fine. Don’t believe me.
They called me an alarmist... When in 2010 I said America’s debt was out of control. When I warned it would unleash a wave of civil unrest, society collapse, inflation, and currency debasement, they called me crazy. When I said the dollar’s reign was coming to an end… that interest payments would one day overwhelm our budget… they said: that’ll never happen here. And yet – here we are. America’s national debt just blew past $37 trillion.
See More Headlines

SNNA Stock Analysis - Frequently Asked Questions

Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) released its earnings results on Thursday, March, 14th. The company reported ($0.93) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by $0.10.

Sienna Biopharmaceuticals (SNNA) raised $64 million in an initial public offering on Thursday, July 27th 2017. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and BMO Capital Markets acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sienna Biopharmaceuticals investors own include SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA), Protalix BioTherapeutics (PLX), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Motif Bio (MTFB) and Ritter Pharmaceuticals (RTTR).

Company Calendar

Last Earnings
3/14/2019
Today
7/01/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SNNA
Fax
N/A
Employees
39
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$73.47 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.27 per share
Price / Book
0.11

Miscellaneous

Free Float
N/A
Market Cap
$4.20 million
Optionable
Not Optionable
Beta
2.67
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:SNNA) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners